Symbiotec Pharmalab Limited
ListedMainboardHealthcare · NSE / BSE
Incorporated in 2002, Symbiotec Pharmalab Ltd. is a pharmaceutical and biotechnology company that develops and manufactures active pharmaceutical ingredients, nutritional ingredients, and specialty products for both domestic and international markets. The company focuses on research-based manufacturing, strong quality standards, and sustainable processes, serving industries like pharmaceuticals, nutraceuticals, and wellness with high-quality and innovative products. With over 30 years of experience, it has grown from a small lab-scale steroid API manufacturer into a large, fully integrated company with approvals from global authorities like the US FDA, EU-GMP, and Korea’s Ministry of Food and Drug Safety. As of June 30, 2025, the company operates two large-scale manufacturing facilities with a chemical synthesis capacity of 584.67 metric tonnes and fermentation capacity of 300 kilolitres.
Price Band
₹938 – ₹988
Issue Size
₹1778.64 L Cr
Lot Size
15 shares
GMP
₹185
+18.7%
Est. Listing
₹1173
at current GMP
Subscribed
75.06x
overall
Open
24 Aug 2026
Close
27 Aug 2026
Allotment
28 Aug 2026
Refund
29 Aug 2026
Demat Credit
30 Aug 2026
Listing
1 Sep 2026
Last updated 27 days ago
Live Grey Market Premium
Symbiotec Pharmalab Limited GMP Today
Last updated: 1 Sept 2026
Current Premium
₹185+18.7%
Issue Price (Upper)
₹988
Band: ₹938 – ₹988
Estimated Listing Price
₹1173
Upper price + GMP
Lot Size
15 shares
Min investment ₹14,820
Estimated Profit / Lot
₹2,775
15 × ₹185
Symbiotec Pharmalab Limited GMP Historical Trend
GMP History
Grey Market Premium trend
+₹185
▲ 0 today
Updated 1 minute ago
Estimated Listing Price
| Date | GMP (₹) | GMP % | Est. Listing |
|---|---|---|---|
| 28 Sep 2026 | +₹185 | 18.7% | ₹1173 |
| 26 Sep 2026 | +₹185 | 18.7% | ₹1173 |
| 25 Sep 2026 | +₹167 | 16.9% | ₹1155 |
GMP is unofficial market data. Not a guarantee of listing performance.
About Symbiotec Pharmalab Limited Public Issue & Market Profile
Symbiotec Pharmalab Limited is bringing an initial public offering (IPO) in the Healthcare sector with an aggregate issue size of ₹1,77,86,442 Crores. The shares are offered at a price band of ₹938 to ₹988 per equity share on NSE and BSE. Currently, market analysts recommend evaluating the company's financial valuation, price-to-earnings (P/E) multiple, and peer comparison prior to submitting bids.
Public Issue & Pricing Context:
The public offer consists of a fresh issue and offer-for-sale structured under SEBI regulations. Bidding is open to Qualified Institutional Buyers (QIB), Non-Institutional Bidders (NII/HNI), and Retail Individual Investors (RII). Applications can be submitted online using ASBA or UPI mandate through certified stock brokers and net banking portals.
Basis of Allotment & Listing Timeline:
Following the close of bidding on 2026-08-27, the basis of allotment is scheduled to be finalized on 2026-08-28. Investors can verify their application status online by submitting their PAN card number, Application Number, or DP Client ID on the registrar's official portal (Link Intime India Private Limited) or the BSE allotment checking window.
Frequently Asked Questions
What is Symbiotec Pharmalab Limited IPO GMP today?
The latest grey market premium for Symbiotec Pharmalab Limited IPO is ₹185, which indicates an expected listing price of ₹1173.
What does Kostak Rate and Sauda mean in IPO GMP?
Kostak rate is the profit amount an investor earns by selling their entire IPO application in the grey market before allotment is finalized.
Is Grey Market Premium officially recognized?
No. GMP is an unofficial indicator discovered between dealers outside of SEBI-regulated exchanges. Actual listing price is determined by demand-supply discovery on NSE/BSE during the pre-open auction.